Bright Minds Biosciences Inc.
DRUG.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$754.59M
Close$
$12.04
83% downside
Current Fair Value
83% downsideOvervalued by 83% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $754.59 Million |
|---|---|
| Enterprise Value | $446.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.78 |
| Beta | 0.09 |
| Outstanding Shares | 9,830,424 |
Return
| Return on Equity | -7.65% |
|---|---|
| Return on Assets | -7.59% |
| Return on Invested Capital | -11.25% |
Valuation & Multiples
| P/E Ratio | -26.59 |
|---|---|
| PEG | 50.12 |
| Price to Sales | - |
| Price to Book Ratio | 2.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -12.87 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-1.68
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 17, 2026
EPS Estimate
$-1.59
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bright Minds Biosciences Inc
26 employees
CEO: Ian McDonald Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agoni...